Lyell Immunopharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top 25 shareholders own 82.48% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14.2%	Arch Venture Partners, L.P.	36,412,716	US$44.4m	0%	3.65%
11.8%	GSK plc	30,253,189	US$36.9m	0%	no data
7.88%	Mwg Management Ltd.	20,162,332	US$24.6m	0%	29.25%
5.9%	Apoletto Limited	15,093,969	US$18.4m	0%	11.12%
5.9%	DST Global	15,093,969	US$18.4m	0%	0.98%
5.27%	BlackRock, Inc.	13,495,132	US$16.5m	-2.86%	no data
5.23%	The Vanguard Group, Inc.	13,398,298	US$16.3m	0.07%	no data
3.25%	Foresite Capital Management, LLC	8,325,000	US$10.2m	0%	2.57%
3.08%	T. Rowe Price Group, Inc.	7,872,369	US$9.6m	16.9%	no data
3%	WuXi PharmaTech Healthcare Fund I General Partner L.P.	7,682,156	US$9.4m	-6.09%	29.22%
2.5%	OrbiMed Advisors LLC	6,405,098	US$7.8m	3,110%	0.1%
2.29%	GV Management Company, LLC	5,865,125	US$7.2m	0%	0.5%
1.83%	Hans Edgar Bishop	4,685,614	US$5.7m	0%	no data
1.57%	Geode Capital Management, LLC	4,012,053	US$4.9m	-0.12%	no data
1.52%	Richard Klausner	3,898,714	US$4.8m	0%	no data
1.49%	State Street Global Advisors, Inc.	3,818,320	US$4.7m	2.7%	no data
1.19%	HongShan	3,045,997	US$3.7m	0%	0.08%
1.07%	FMR LLC	2,733,462	US$3.3m	-1.29%	no data
0.68%	Mic Capital Management Uk Llp	1,740,569	US$2.1m	0%	0.42%
0.65%	Opaleye Management Inc.	1,670,000	US$2.0m	-50.2%	0.32%
0.54%	Northern Trust Global Investments	1,389,041	US$1.7m	-3.67%	no data
0.51%	Charles Schwab Investment Management, Inc.	1,297,642	US$1.6m	1.42%	no data
0.39%	TD Asset Management, Inc.	1,004,642	US$1.2m	4.23%	no data
0.38%	Balyasny Asset Management L.P.	985,336	US$1.2m	316%	no data
0.32%	Millennium Management LLC	809,560	US$987.7k	-60.3%	no data